1 / 27

Myeloproliferative Disorder

Myeloproliferative Disorder. STEM CELL DISORDERS WHEREBY YOU GET ABNORMAL PROLIFERATION IN ONE OR MORE CELL LINE DERIVED FROM A COMMON STEM CELL. THE INDIVIDUAL FEATURE OF THESE DISEASE S RESULT FROM A: DISTURBED HAEMOPOIETIC MICROENVIRONMENT CLONAL ABNORMALITY

Download Presentation

Myeloproliferative Disorder

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Myeloproliferative Disorder STEM CELL DISORDERS WHEREBY YOU GET ABNORMAL PROLIFERATION IN ONE OR MORE CELL LINE DERIVED FROM A COMMON STEM CELL

  2. THE INDIVIDUAL FEATURE OF THESE DISEASES RESULT FROM A: • DISTURBED HAEMOPOIETIC MICROENVIRONMENT • CLONAL ABNORMALITY • DISTURBANCE IN HAEMOPOIETIC REGULATION.

  3. Myeloproliferative Disorder • Polycythaemia Ruba Vera • Myelofibrosis • Primary Thrombocytopenia • Chronic Myeloid Leukaemia • Myeloproliferative Disorder – unclassifiable • Chronic Eosinophilic Leukaemia • Chronic Myeloid Leukaemia

  4. CMPD- COMMON FEATURES • Proliferation and differention of one or more stem cell. • Raised W.C.C.. HB, Platelets • Organomegaly • Extramedullary Haematopoiesis • Clinical, Laboratory and Morphological overlap

  5. CMPD • Disease of Adults • Peak Onset 50-70 • 6-9/100,000 • Limited Geographical Based Data

  6. PRIMARY THROMBOCYTHAEMIA PLATELETS > 600 X 109/L ^ MEGAKARYOCYTES IN THE MARROW CLONAL DISORDER OF THE MULTIPOTENTIAL STEM CELL

  7. Primary Thrombocythaemi - Pathogenesis Aetiology – Unknown Megakaryocytic hyperplasia Functionally abnormal platelets

  8. Primary ThrombocythaemiaClinical Features • Asymptomatic • Vasomotor- 40% • Haemorrhage – 25% • Thrombosis – 20% • Splenomegaly • Recurrent Miscarriage

  9. PRIMARY THROMBOCYTOSIS DIAGNOSTIC CRITERIA PLATELET COUNT > 600X109/L FOR OVER 2 MONTH WITH NO CAUSE OF REACTIVE THOMBOCYTOSIS, NO EVIDENCE OF PRV, MYELOFIBROSIS, MYELODYSPLASIA AND NO PH CHROMASOME

  10. PRIMARY THOMBOCYTOSIS DIAGNOSIS: EXCLUDE CAUSE OF REACTIVE THROMBOCYTOSIS. EG: ACUTE HAEMORRHAGE MALIGNANT DISEASE, CHRONIC INFLAMM DISORDER, ACUTE INFLAM POST-OP SPLENECTOMY EXERCISE IRON DEF.

  11. PRIMARY THROMBOCYTHAEMIA TREATMENT MYELOSUPPRESIVE HYROXUREA ANAGRELIDE ANTI-PLATELET AGENTS INTERFERON

  12. POLYCYTHAEMIA • Absolute polycythaemia • Relative polycythaemia

  13. ABSOLUTE POLYCYTHAEMIA . PRIMARY POLYCYTHAEMIA - POLYCYTHAEMIA RUBRA VERA - ERYTHROPOIETIC RECEPTOR GENE MUTATION. 2. SECONDARY POLYCYTHAEMIA - HYPOXAEMIA POO < 92% - RENAL DISEASE - TISSUE HYPOXIA - HIGH AFFINITY HB - TUMOURS - HEPATOMAS, FIBROIDS, CEREBELLAR - HAEMANGIOBLASTOMAS - HIGH ERYTHROPOIET PRODUCTION 3 IDIOPATHIC ERYTHROCYTOSIS.

  14. CLINICAL FEATURES OF P.R.V • Older Age - 50 - 60, Female > Male • Vascular Complications - Arterial = Venous • Cerebral + Coronary - Headache - Dizziness • Due to Small Vessel Occlusion. • => 30-50% - Thrombotic - Art = Venus, Sml & Lrg Vessels • - Haemorrhagic • Peptic Ulceration - ^ Histamine Levels • Prutritis - 20-25% • Skin Change - Pletharic Facies, Acne Roscea,

  15. CLINICAL FEATURES OF P.R.V. CONTD. ^ URIC ACID - GOUT ^ BP SPLENOMEGALY - 50% LAB * ^HB ^PCV - MALE - HB 17.5G/L, PCV > 0.51 - FEMALE HB15.5G/L, PCV > 0.46 ^ WCC ^PLATELETS 50% - 400 - 800X 109/L ^ B12 LEUCOCYTE ALKALINE PHOSPHATASE. MARROW - HYPERCELLUAR

  16. DIAGNOSTIC CRITERIA OFPPP OR PRV ^RCM > 36ML/KG IN MALES - 32ML/KG IN FEMALES NO EVIDENCE OF A CAUSE OF SECONDARY POLYCYTHAEMIA INCLUDING ARTERIAL OXYGEN SATURATION > 92% + SPLENOMEGALY (PALPABLE) IF (-) SPLENOMEGALY PALPABLE - PLATELET > 400 - ^WCC > 12 - ^ LAP/^B12 COURSE: 15-20% - MYELOFIBROSIS 2-10% - ACUTE LEUKAEMIA RX VENESECTION REGULARILY CHEMOTHERAPY , HYDROXYREA ANTIPLATELET THERAPY

  17. Investigation of Polycythaemia • RED CELL MASS STUDIES AIM IS TO INVESTIGATE/EXCLUDE A CAUSE OF SECONDARY POLYCYTHAEMIA • CLINICAL EVALUATION • PULSE OXIMETRY • RENAL - URINALYSIS + RENAL ULTRASOUND • ABDOMINAL ULTRASOUND • NEUTROPHIL COUNT • PLATELET COUNT • MARROW CYTOGENETICS • MARROW CULTURE • SERUM ERYTHROPOIETIN ASSAYS.

  18. MANAGEMENT OF P.R.V • PREVENTION OF VASCULAR OCCLUSIONS • DELAY MYELOFIBROTIC TRANSFORMATION • MINIMIZE ACUTE LEUKAEMIC TRANSFORMATION. • PHLEBOTOMY • MYELOSUPPRESSIVE • ANTIPLATELET AGENT.

  19. P.R.V. COURSE: 15-20% - MYELOFIBROSIS 2-10% - ACUTE LUEKAEMIA RX: VENESECTION REGULARLY CHEMOTHERAPY 35p HYDROXYURIA ANTIPLATELET THERAPY

  20. MYELOFIBROSIS(agnogenic myeloid metaplasia) 1o DISORDER - OR - AS PART OF OTHER MYELOPROLIFERATIVE DISORDERS 20% HAVE HX OF PRV 2ND LYMPHOPROLIFERATIVE, BENZENE, FLUORINE, ANSENIC

  21. MYELOFIBROSIS(agnogenic myeloid metaplasia) PATHOLOGY: ^ Connective tissue within the bone marrow. ^ Collagen ^ New bone formation destruction of normal marrow microenvironment ^ circ stem cells: cells normally present in the marrow Dysplastic Feature. Extramedullary haemopoiesis - eg. liver.

  22. MYELOFIBROSIS(agnogenic myeloid metaplasia) SYMPTOMS: OFTEN ASYMPTOMATIC: BONE MARROW FAILURE ^ SPLEEN - LUQ PAIN METABOLIC CONSEQUENCE OF M/P DISORDER - SWEATS ^URIC ACID GOUT, RENAL COLIC BLEEDING DIATHESIS

  23. Myeloproliferative DisordersChronic Granulocytic Leukaemia • First malignancy associated with a recurring chromosomal abnormality • Translocation of genetic material from chromosomes 9 22 • Fusion gene fusion protein - pathogenesis

  24. CHRONIC GRANULOCYTIC LEUKAEMIA = CHRONIC MYELOID LEUKAEMIA 1/100,000 MALE > FEMALE 5TH - 6TH DECIDE BUT CAN OCCUR AT ANY AGE PH CHROMOCOSME - RECIPROCAL TRANSLOCATION BETWEEN CHROMOSOME 9 => 22 = ? AETIOLOGICAL SIGNIFICANCE OR ? MARKER DISEASE. => CLONAL DISORDER OF HAEMOPOIETIC STEM CELL ? PROCESS - GROWTH ADVANTAGE => X 30 FIELD ^ IN GRANULOCTE MASS

  25. C.G.L. CLINICAL FEATURES: BIPHASIC OR TIRPHASIC DISEASE CRONIC ACCELERATED TRANSFORMATION 20% ASYMPTOMATIC NON-SPECIFIC COMPLAINTS SPLENAMEGALY AND HEPATOMEGALY

  26. C.G.L. LAB FEATURES: LEUCOCYTOSIS - 100 -300 x 109/L. BASOPHILIA THROMBOCYTOSIS HYPERCELLULAR MARROW PH POSITIVE IN 90% INCREASED MARROW FIBROSIS.

  27. C.G.L. TREATMENT OF C.G.L: BONE MARROW TRANSPLANT CYTOREDUCTIVE THERAPY TYROSINE KINASE INHIBITORS E.G. HYDROXYUREA, INTERFERON MANAGEMENT OF METABOLIC COMPLICATIONS.

More Related